ClinicalTrials.gg
Active, not recruitingNCT06003231Updated Jul 22, 2026

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

A Phase 2 interventional study of disitamab vedotin in Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms and Endometrial Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 96 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
51st of 136
120 · median 79
Started
2023
with 5 others
Phase 2
45 of 158
3 open now
Primary completion
2026-03
later than 2 of 25 live
Registered
132nd of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 51st largest by enrollment of the 136 interventional ones that give a count, is one of 6 that started in 2023, is one of 45 in phase 2, reaches primary completion later than 2 of the 25 other live ones, and was the 132nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2.

This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks.

This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Head and Neck Neoplasms

Keywords

  • NSCLC
  • Ovarian Cancer
  • Endometrial Cancer
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: Head and neck cancer (HNC)

    • Must have -documented carcinoma of the head and neck with primary tumor site arising from the oral cavity, salivary gland, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded.
    • Unresectable locally recurrent or stage disease
    • Prior therapies:

      • Participants must have disease progression after treatment with a platinum-based therapy
  • Cohort 2: Non-small cell lung cancer (NSCLC)

    • Pathologically documented NSCLC
    • Unresectable locally-advanced or metastatic stage disease
    • Prior therapies

      • Must have progressed during or after a platinum-based therapy for LA/metastatic disease or, within 6 months of platinum-based adjuvant, , or concomitant chemoradiotherapy for early or locally-advanced stage disease
      • Must have received prior anti-PD(L)1 therapy, unless
      • Participants with known AGAs must have received appropriate targeted therapy, where available.
      • No more than 2 prior lines of cytotoxic chemotherapy for advanced disease
  • Cohort 3: Ovarian Cancer

    • Pathologically documented epithelial cancers of ovarian, fallopian tube, or peritoneal origin
    • Unresectable locally-advanced or metastatic stage disease
    • Prior therapies

      • Must have platinum resistant disease (6 months or less between the completion of platinum-based treatment and identification of recurrence)
      • Must not have received more than 4 lines of prior cytotoxic chemotherapies for advanced disease
      • Participants with known BRCA mutations are permitted, but participants must have received targeted therapy with a PARP inhibitor
      • May have received prior anti-PD(L)1 therapy
  • Cohort 4: Endometrial Cancer

    • Must have pathologically documented adenocarcinoma of the endometrium
    • Must have unresectable locally-advanced or metastatic stage disease.
    • Prior therapies

      • Must have /progressed after at least one prior platinum-based chemotherapy for recurrent, metastatic or primary unresectable disease
      • Must not have received more than 3 lines of prior cytotoxic chemotherapies for advanced disease
      • May have received prior anti-PD(L)1 therapy
  • expression of 1+, 2+, or 3+, as determined by local IHC testing on a fresh or . Note: Participants with HER2 mutations are eligible.
  • per v1.1 criteria as assessed by the investigator
  • Able to provide formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides)
  • (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an MMAE-containing agent.
  • Known to any contained in the drug formulation of disitamab vedotin.
  • History of another invasive within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
  • Active untreated CNS or
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Head and neck cancer

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Non-small cell lung cancer

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Ovarian cancer

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

  • Experimental
    Endometrial cancer

    Disitamab vedotin monotherapy

    Drug: disitamab vedotin

Interventions

  • Given into the vein (IV, intravenous) every 2 weeks

    Also known as: RC48, RC48-ADC

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment

    The proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator

    Time frame: Approximately 3 years

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Through 30-37 days after the last dose of DV; approximately 5 years

  2. Number of participants with laboratories abnormalities

    Time frame: Through 30-37 days after the last dose of DV; approximately 5 years

  3. Number of participants with dose alterations due to AEs

    Time frame: Approximately 5 years

  4. Confirmed Disease Control Rate (DCR) per RECIST v1.1 by investigator assessment

    The proportion of participants with stable disease (SD) or confirmed CR or PR according to RECIST v1.1

    Time frame: Approximately 5 years

  5. Duration of Response (DOR) per RECIST v1.1 by investigator assessment

    The time from start of the first documentation of objective tumor response of CR or PR (that is subsequently confirmed) to the first documentation of progressive disease (PD) per RECIST v1.1, or to death due to any cause

    Time frame: Approximately 5 years

  6. Progression free survival (PFS) per RECIST v1.1 by investigator assessment

    PFS is defined as the time from the start of study treatment to the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first

    Time frame: Approximately 5 years

  7. Overall Survival (OS)

    The time from the start of study treatment to the date of death due to any cause

    Time frame: Approximately 5 years

  8. Pharmacokinetic (PK) parameter - Area under the concentration-time curve to the time of the last quantifiable concentration (AUClast)

    Analyzed through cycle 2.

    Time frame: Approximately 1 month

  9. PK parameter - Maximum concentration (Cmax)

    Analyzed through end of treatment.

    Time frame: Through 30-37 days after the last dose of DV; approximately 5 years

  10. PK parameter - Trough concentration (Ctrough)

    Analyzed through end of treatment.

    Time frame: Through 30-37 days after the last dose of DV; approximately 5 years

  11. Incidence of antidrug antibodies (ADAs)

    Time frame: Through 30-37 days after the last dose of DV; approximately 5 years

07

Study locations

96 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2026, 28 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 28 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 21, 2023
StartActual
Nov 14, 2023
Primary completionActual
Mar 27, 2026
CompletionEst.
May 31, 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06003231
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Nov 14, 2023
Primary completion
Mar 27, 2026
Completion
May 31, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion